Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
People's Hospital of Zhengzhou University & Henan Eye Institute, Zhengzhou, 450000, China.
BMC Ophthalmol. 2022 May 6;22(1):205. doi: 10.1186/s12886-022-02409-8.
To report the multimodal imaging and treatment of fifteen retinal capillary hemangioblastomas (RCHs) associated with Von Hippel-Lindau syndrome in a monocular patient during a long-term following-up, which supply high-resolution exquisite SS-OCTA images (VG200; SVision Imaging, Ltd., Luoyang, China) and management experience about multiple RCHs.
A 34-year-old monocular male patient complained decreased visual acuity (20/100) without pain and redness in the left eye five years ago. Von Hippel-Lindau syndrome were diagnosed with genetic testing. He, his son and daughter all carried a heterozygosity missense variant c.499C > T (p. Arg167Trp) in the Hg19 gene, a VHL gene located in Chr3:10,191,506. Fifteen RCHs were identified by the application of multimodal imaging, which including fundus photo, fundus autofluorescence (FAF), B-scan ultrasonography (US), fluorescein fundus angiography (FFA), indocyanine green angiography (ICGA) and swept-source optical coherence tomography angiography (SS-OCTA). Transscleral cryotherapy and laser photocoagulation were performed to destroy the largest RCH with the size of 4 PD in diameter. Laser photocoagulation was conducted to seal the middle or tiny RCHs (< 1.5 PD) and their nourishing vessels. The retinal edema and exudative macular detachment were successfully relieved by intraocular injection of bevacizumab for 5 times. The RCHs in the left eye responded well to these treatments and best corrected visual acuity was 20/25 for three years. Three-month recall visits were recommended for him.
For multiple retinal capillary hemangioblastomas in monocular patients, precise combined therapy guided by multimodal imaging has a profound impact on the management of new and recurrent RCHs.
报告 1 例单侧发病的von Hippel-Lindau 综合征(VHL 综合征)合并视网膜毛细血管血管瘤(RCH)患者的长期随访中 15 个 RCH 的多模态影像学表现和治疗经过,为其提供高分辨率的精细血流 OCTA 成像(VG200;SVision Imaging,Ltd.,洛阳,中国),并总结了对多个 RCH 的管理经验。
一位 34 岁的男性单侧发病患者 5 年前左眼无疼痛和红肿的情况下出现视力下降(20/100)。基因检测诊断为 VHL 综合征。他、他的儿子和女儿均携带位于 Chr3:10,191,506 的 VHL 基因 Hg19 区 c.499C > T(p.Arg167Trp)杂合错义变异。通过多模态成像发现 15 个 RCH,包括眼底照相、自发荧光(FAF)、B 型超声(US)、荧光素眼底血管造影(FFA)、吲哚青绿血管造影(ICGA)和扫频源光学相干断层扫描血管造影(SS-OCTA)。对最大的直径为 4 PD 的 RCH 进行经巩膜冷冻治疗和激光光凝以破坏肿瘤,对中等或微小的 RCH(<1.5 PD)及其供养血管进行激光光凝以封闭血管。5 次玻璃体内注射贝伐单抗成功缓解视网膜水肿和黄斑渗出性脱离。左眼的 RCH 对这些治疗反应良好,3 年来最佳矫正视力为 20/25。建议他每 3 个月进行一次复查。
对于单侧发病的多发性 RCH,多模态影像学引导的精准联合治疗对新发病灶和复发病灶的管理有重要影响。